Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial
Authors:
Top Cited Papers
- 1 October 2021
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 398 (10310) , 1498-1506
Abstract
No abstract availableKeywords
Funding Information
- Bayer HealthCare
- STROKE-Riksförbundet
- Boehringer Ingelheim GmbH
- Forskning och Utveckling Halland
- Pfizer Ltd
- Stiftelsen Tornspiran
- Bristol-Myers Squibb Co
- Hjärt-Lungfonden
- Stockholm County Council
- King Gustaf V and Queen Victoria's Masonic Foundation
This publication has 28 references indexed in Scilit:
- The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysisEuropean Heart Journal, 2016
- Mass Screening for Untreated Atrial FibrillationCirculation, 2015
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014
- Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP)EP Europace, 2012
- External review and validation of the Swedish national inpatient registerBMC Public Health, 2011
- Apixaban in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Validation of the Swedish inpatient and cause-of-death registers in the context of strokeActa Neurologica Scandinavica, 2011
- Non‐attendance in breast cancer screening is associated with unfavourable socio‐economic circumstances and advanced carcinomaInternational Journal of Cancer, 2003
- Antithrombotic Therapy To Prevent Stroke in Patients with Atrial FibrillationAnnals of Internal Medicine, 1999
- Stroke Severity in Atrial FibrillationStroke, 1996